The people being asked to participate in this study have type 2 diabetes and abnormal levels
of protein in their urine. This indicates that they are starting to develop diabetic kidney
disease. The standard treatment for this is the use of one of two blood pressure medicines,
either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker
(ARB). However, these medicines are not always completely effective in stopping/reversing the
kidney disease. Some studies have previously suggested that another type of medicine, called
sitagliptin, normal used to treat diabetes may also help prevent diabetic kidney disease from
getting worse.
This study is being performed to test the effectiveness of sitagliptin as compared to a
placebo, along with a stable dose of an ACE inhibitor or ARB, to determine whether or not it
will reduce protein levels in their urine. Protein levels in the urine are a marker of the
severity of kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
University of Missouri-Columbia
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate